Application of Bionanomaterials in Tumor Immune Microenvironment Therapy

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td class="align_left">Type of cells</td><td class="align_center">Receptors</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td class="align_left">Tumor-associated macrophages</td><td class="align_center">CD86, CD206, CD163, HLA-DR, CD11b, F4/80, MHC-II</td></tr><tr><td class="align_left">Myeloid-derived suppressor cells</td><td class="align_center">CD11b, CD14, CD15, CD66b, Ly6C, Ly6G</td></tr><tr><td class="align_left">Dendritic cells</td><td class="align_center">CD11c, MHC-II, CD1a</td></tr><tr><td class="align_left">T lymphocyte cells</td><td class="align_center">CD3, CD4, CD8, FOXP3, CD45RO, PD-1</td></tr><tr><td class="align_left">Cancer-associated fibroblasts</td><td class="align_center">GPR77, CD10, <i>α</i>SMA, FAP</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Main overexpressing receptors that could be targeted in TIME.</div>

Journal of Immunology Research

tab2

Table 2

Table 2: Application of Bionanomaterials in Tumor Immune Microenvironment Therapy 